Guobao Huang1, Qiang Jiang1, Mei Li2, Yong Lu1, Zhen Wang1. 1. Department of Ophthalmology, Jinan Central Hospital Affiliated to Shandong University Ji'nan 250013, P.R. China. 2. Jiaozhou Central Hospital of Qingdao Qingdao 266300, P.R. China.
Abstract
PURPOSE: This study was designed to explore the characteristics and therapy of cytomegalovirus retinitis (CR) in patients diagnosed with acquired immunodeficiency syndrome (AIDS). METHODS: A total of 67 AIDS patients (78 eyes) with CR findings of were collected from January 2009 to January 2013. The correlation between CR, cellular immunity, risk factor, clinical characteristics, treatment and prognosis of CR was assessed. The incidence of CR in different CD4+T lymphocyte count groups was analyzed. RESULTS: Among all participants, 58 were male and 9 females, aged from 18-60 years, (38±9) years on average. CD4+ T lymphocyte count of CR patients ranged from 0-141 cells/µl and < 50 cells/µl in 81.3% of cases. CR was the primary manifestation in 10.2%, retinal lesions in 25.1%, best corrected visual acuity (BCVA) < 0.3 in 54% of AIDS patients. Retinal necrosis was involved near the posterior pole in 62.5% of CR patients. The visual acuity of 60 (47.6%) eyes was improved after treatment and 94.1% cases were cured within 3 months. Anti-CMV treatments including induction and maintenance of ganciclovir or foscarnet were discontinued when CD4+T lymphocyte count was > 150 cells/µl for three consecutive months. Complicated cataract, retinal detachment and immune reconstitution uveitis were observed in 20.5%, 12.1% and 13.1% of cases, respectively. CONCLUSION: Decreased CD4+T lymphocyte count is a risk factor for CR. HAART and anti-CMV therapy are efficacious treatment of CR. Conventional eye examinations should be conducted to early diagnose CR or other opportunistic infections in all AIDS patients.
PURPOSE: This study was designed to explore the characteristics and therapy of cytomegalovirus retinitis (CR) in patients diagnosed with acquired immunodeficiency syndrome (AIDS). METHODS: A total of 67 AIDSpatients (78 eyes) with CR findings of were collected from January 2009 to January 2013. The correlation between CR, cellular immunity, risk factor, clinical characteristics, treatment and prognosis of CR was assessed. The incidence of CR in different CD4+T lymphocyte count groups was analyzed. RESULTS: Among all participants, 58 were male and 9 females, aged from 18-60 years, (38±9) years on average. CD4+ T lymphocyte count of CR patients ranged from 0-141 cells/µl and < 50 cells/µl in 81.3% of cases. CR was the primary manifestation in 10.2%, retinal lesions in 25.1%, best corrected visual acuity (BCVA) < 0.3 in 54% of AIDSpatients. Retinal necrosis was involved near the posterior pole in 62.5% of CR patients. The visual acuity of 60 (47.6%) eyes was improved after treatment and 94.1% cases were cured within 3 months. Anti-CMV treatments including induction and maintenance of ganciclovir or foscarnet were discontinued when CD4+T lymphocyte count was > 150 cells/µl for three consecutive months. Complicated cataract, retinal detachment and immune reconstitution uveitis were observed in 20.5%, 12.1% and 13.1% of cases, respectively. CONCLUSION: Decreased CD4+T lymphocyte count is a risk factor for CR. HAART and anti-CMV therapy are efficacious treatment of CR. Conventional eye examinations should be conducted to early diagnose CR or other opportunistic infections in all AIDSpatients.
Authors: Janet T Holbrook; Ryan Colvin; Mark L van Natta; Jennifer E Thorne; Mark Bardsley; Douglas A Jabs Journal: Am J Ophthalmol Date: 2011-07-13 Impact factor: 5.258
Authors: Jennifer E Thorne; Janet T Holbrook; Douglas A Jabs; John H Kempen; Charles Nichols; Curtis L Meinert Journal: Ophthalmology Date: 2006-11-22 Impact factor: 12.079
Authors: William G Hodge; Jean-François Boivin; Stanley H Shapiro; Richard G Lalonde; Kirtida C Shah; Bradley D Murphy; Francisco Diaz-Mitoma Journal: Can J Ophthalmol Date: 2004-12 Impact factor: 1.882
Authors: M Dujić; Dj Jevtović; D Salemović; J Ranin; B Brmbolić; O Djurković-Djaković Journal: Biomed Pharmacother Date: 2008-01-14 Impact factor: 6.529